Quarterly ResultAug 5, 2026, 04:09 PM
Biomea Fusion Reports Q2 Net Loss $8.3M; Advances Diabetes & Obesity Trials
AI Summary
Biomea Fusion, Inc. reported a net loss of $8.3 million for the second quarter ended June 30, 2026, a significant reduction from $20.7 million in the same period last year, with R&D expenses also decreasing. The company provided updates on its clinical programs, including ongoing Phase II trials for icovamenib in Type 2 diabetes with data expected in Q1 and Q2 2027. Initial 28-day weight reduction data from the Phase I GLP-131 (BMF-650) obesity trial is anticipated in Q3 2026, and a new Phase II collaboration for icovamenib in obesity was announced. The company projects its cash runway into Q2 2027.
Key Highlights
- Net loss attributable to common stockholders was $8.3 million for Q2 2026, down from $20.7 million in Q2 2025.
- Research and development expenses decreased to $9.1 million in Q2 2026 from $16.6 million in Q2 2025.
- Cash, cash equivalents, and restricted cash totaled $35.2 million as of June 30, 2026.
- Cash runway is projected into the second quarter of 2027.
- Phase II COVALENT-211 (T2D) data expected in Q1 2027.
- Phase II COVALENT-212 (T2D) data expected in Q2 2027.
- Initial 28-day weight reduction data for BMF-650 (obesity) Phase I expected in Q3 2026.
- Research collaboration initiated with University of Leicester for icovamenib in obesity.
Price Impact
More from BMEA